CA2306982A1 - Utilisation de moxonidine pour le traitement de la depression - Google Patents

Utilisation de moxonidine pour le traitement de la depression Download PDF

Info

Publication number
CA2306982A1
CA2306982A1 CA002306982A CA2306982A CA2306982A1 CA 2306982 A1 CA2306982 A1 CA 2306982A1 CA 002306982 A CA002306982 A CA 002306982A CA 2306982 A CA2306982 A CA 2306982A CA 2306982 A1 CA2306982 A1 CA 2306982A1
Authority
CA
Canada
Prior art keywords
moxonidine
depression
treatment
pharmaceutically
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306982A
Other languages
English (en)
Inventor
Michael Francis O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Eli Lilly and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co Ltd filed Critical Eli Lilly and Co Ltd
Publication of CA2306982A1 publication Critical patent/CA2306982A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention se rapporte à l'utilisation de moxonidine, ou d'un sel d'addition acide pharmaceutiquement acceptable de moxonidine, dans la préparation d'un médicament destiné à traiter un trouble du système nerveux central.
CA002306982A 1997-10-17 1998-10-09 Utilisation de moxonidine pour le traitement de la depression Abandoned CA2306982A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9721978.6 1997-10-17
GBGB9721978.6A GB9721978D0 (en) 1997-10-17 1997-10-17 Treatment of depression
PCT/GB1998/003032 WO1999020278A1 (fr) 1997-10-17 1998-10-09 Utilisation de moxonidine pour le traitement de la depression

Publications (1)

Publication Number Publication Date
CA2306982A1 true CA2306982A1 (fr) 1999-04-29

Family

ID=10820690

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306982A Abandoned CA2306982A1 (fr) 1997-10-17 1998-10-09 Utilisation de moxonidine pour le traitement de la depression

Country Status (6)

Country Link
EP (1) EP1023070A1 (fr)
JP (1) JP2001520194A (fr)
AU (1) AU9359898A (fr)
CA (1) CA2306982A1 (fr)
GB (1) GB9721978D0 (fr)
WO (1) WO1999020278A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251949A1 (en) * 2002-07-18 2004-02-09 Vanderbilt University Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype

Also Published As

Publication number Publication date
EP1023070A1 (fr) 2000-08-02
WO1999020278A1 (fr) 1999-04-29
JP2001520194A (ja) 2001-10-30
AU9359898A (en) 1999-05-10
GB9721978D0 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
US5145852A (en) Vaso-active medicament to treat impotence
JPH0643299B2 (ja) 薬剤療法
KR20140136982A (ko) 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
HU217833B (hu) Eljárás difenil-butil-piperazin-karboxamidokat tartalmazó, mértéktelen szerfogyasztásból eredő betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
EP0244080A2 (fr) Médicament pour le traitement de l'obésité
AU2010211491B2 (en) Medical use of 5-benzylaminosalicylic acid derivative or its salt
US20130225559A1 (en) S-mirtazapine for the treatment of hot flush
CN110545819A (zh) 用于治疗高血压的组合物
CA2383146C (fr) Agent therapeutique contre la douleur neuropathique et modele animal de douleur neuropathique
CN110573148A (zh) 特发性肺纤维化的治疗
SK14582002A3 (sk) Použitie bradykardických látok a voliteľne jednej ďalšej zlúčeniny pôsobiacej na srdce
US4618621A (en) Method for treating medical conditions involving cerebral ischemia
CA2306982A1 (fr) Utilisation de moxonidine pour le traitement de la depression
Li et al. Anorectic Toxicity of Dih Ydroartemisinin, Artemether, and Arteether in Rats Following Multiple Intramuscular Doses
US3497596A (en) Method of treating parkinsonism with morphanthridine derivatives
US5977121A (en) Use of moxonidine for the treatment of atherosclerosis
KR20010105418A (ko) 기분 장애 치료용 오사네턴트
JPS5823618A (ja) 精神分裂症を治療する組成物
Markowitz et al. Comparison of meclofenamate sodium with buffered aspirin and placebo in the treatment of postsurgical dental pain
US5232950A (en) Method for using ketamine for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
NZ502842A (en) Raloxifene for lowering platelet counts
CN1970079A (zh) 重组人干扰素α2a阴道泡腾片及其制备方法
CA1280694C (fr) Methode d'utilisation de la ketamine pour la prevention ou la reduction des effets d'un accident vasculaire cerebral chez un sujet a risque
Kristoffersen et al. Chlormethiazole (Heminevrin®), pethidine and nitrous oxide as compared to halothane for general anaesthesia
WO2024102802A1 (fr) Zélatriazine pour le traitement de la dépression

Legal Events

Date Code Title Description
FZDE Dead